News

Governor Youngkin Announces Expansion of Life Sciences in Prince William County, Creating up to 70 New Jobs

~ Virongy Biosciences Inc. to invest $471,000 to begin development of diagnostic technologies for viral pathogens ~

RICHMOND, VA – Governor Glenn Youngkin announced that Virongy Biosciences Inc., a developer of viral diagnostic technologies, anti-viral drugs, and therapeutic viral vectors, will invest $471,000 to expand in Prince William County. The company recently relocated to occupy over 2,000 square feet of the Northern Virginia Bioscience Center, where it will begin to develop new diagnostic technologies to monitor and quantify SARS-CoV-2 variants and other viral pathogens. The expansion project will create up to 70 new jobs.
“Prince William County has emerged as a hub for the life sciences industry, offering the infrastructure, R&D assets, and talent to attract and retain innovative biotech firms like Virongy,” said Governor Youngkin. “We applaud the company for its groundbreaking developments that will have a positive and far-reaching impact on bioscience advancements and disease prevention and treatment.”
“Virongy’s expansion in Prince William County reinforces the region’s robust industry talent, world-class education institutions, and advanced culture of innovation that supports the company’s mission,” said Secretary of Commerce and Trade Caren Merrick. “We thank Virongy for creating valuable jobs while improving the health of our communities, and look forward to its continued growth in Virginia.”
“Virongy Biosciences Inc. chose Virginia as its company location mainly because it is inside the rapid-growing biotech park of Prince William County, and right beside the Science and Technology Campus of George Mason University,” said Virongy’s Chief Scientific Officer Brian Hetrick.
“I toured the Virongy Biosciences lab at the Northern Virginia Bioscience Center’s grand opening in March, and I was impressed not only by the important discoveries from the Virongy team, but moreover the business’ dedication to hiring from and growing the local talent pool of life sciences employees,” said Chair Ann B. Wheeler, Prince William County Board of Supervisors. “Over the last two years, Prince William County saw significant growth and advancement in the biotechnology industry, and this is validation that we are one of the fastest-growing bio-clusters in the state.”
“I’m excited to see the expansion of a critical arm of the healthcare sector as we continue to build on our successful local economy in Prince William,” said Senator Jeremy S. McPike. “I look forward to working with Virongy.”
“The field of bioscience has made great strides in the last several years,” said Delegate Michelle Maldonado. “With Northern Virginia’s Bioscience Center here in District 50, we are joining this conversation with critical research, contributions, and impact for the Commonwealth through jobs, health solutions, and more. I am excited for Virongy’s expansion in our community and look forward to partnering together for the benefit of all Virginians.”
Established in 2014, Virongy focuses on creating cutting-edge technologies in virology, viral vector-based gene therapy, virus-host cell biology, and viral immunology. The company develops new technologies that can be used for scientific discoveries, clinical diagnostics, and disease treatment. Virongy has discovered and developed key technologies and products including rapid quantitative COVID-19 neutralizing antibody test, Infectin, Cellment, HIV Rev-dependent Lentiviral Vector, and HIV drug and neutralizing antibody discovery technologies. The company’s mission is to provide scientists and clinicians with innovative technologies for studying viruses and viral vectors, and to provide virological services that meet the highest academic and industry standards, facilitating scientific discoveries, clinical diagnostics, and disease treatment.
The Virginia Economic Development Partnership worked with Prince William County to secure the project for Virginia and will support Virongy’s job creation through the Virginia Jobs Investment Program (VJIP), which provides consultative services and funding to companies creating new jobs in order to support employee recruitment and training activities. As a business incentive supporting economic development, VJIP reduces the human resource costs of new and expanding companies. VJIP is state-funded, demonstrating Virginia’s commitment to enhancing job opportunities for citizens.

Recent News

07/15/2025

CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules

CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, announced the closing of its best-efforts offering of 1,500,000 shares of its common stock. Each share of common stock was sold at an offering price of $3.82 per share, priced at-the-market under NYSE American rules. Total gross proceeds from the

07/15/2025

Civica Appoints Dave Sehgal as Chief Manufacturing Officer and Supply Chain Officer

Civica announced the appointment of Dave Sehgal, Ph.D. as its new Chief Manufacturing Officer and Supply Chain Officer, effective July 21. In this role, Dr. Sehgal will lead Civica’s manufacturing strategy and operations, reporting directly to Ned McCoy, President and CEO. “We are excited to welcome Dave to our leadership team,” said McCoy. “His deep

07/14/2025

Nanochon Announces Health Canada Approval for First in Human Investigation

Nanochon, a Washington, DC and Baltimore, MD-based orthopedic device biotech company developing an implant for treating articular cartilage defects in the knee, is thrilled to announce that it was granted Health Canada approval for their first in human clinical trial. The trial will be led by Principal Investigator, Dr. Fathi Abuzgaya, who will collaborate with